State-of-the-art expertiseState-of-the-art expertise
Life sciencesLife sciences

A booming industry in Québec City's metropolitan region

Key figures

128 companies
7,100 jobs, including
3,500 estimated research jobs
$1.5 CDN billion estimated in sales
85 centers, research chairs, clusters and institutes

Data compiled for the Québec City metropolitan region

With a state-of-the-art expertise in biopharmaceuticals, diagnostics, natural health products (cosmeceuticals and nutraceuticals), medical technologies and information technologies related to health, the Québec City metropolitan region is ideally positioned for a growing market. The global market of pharmaceutical products alone should double before 2020 to reach CDN $1.8 billion (PricewaterhouseCoopers 2010)-and the life sciences industry in the Québec City metropolitan region is set to reap the benefits.

Leaders with state-of-the-art expertise

The Québec City metropolitan region is distinguished by leaders and innovative companies with state-of-the-art expertise:

Key university hospital research centers

Investing in a favourable business environment

With a thriving life sciences industry, the Québec City metropolitan region benefits from ongoing and future investments (2010):

  • Expansion and renovation of Hôtel-Dieu Hospital, Québec City - CDN $635 million
  • Modernization of vaccine production facility, GSK - $90 M CA GSK - CDN $90 million
  • New R&D Center and production facility, BD GeneOhm - CDN $50 million
  • Otto Bock / Victhom Human Bionics - CDN $30 million
  • Obesity research laboratories, CRIUCPQ - CDN $28 million

According to KPMG's 2010 Competitive Alternatives report, operating costs in the Québec City metropolitan region are lower than the average for North American cities in clinical trials (27%), biomedical R&D (20%) and manufacturing pharmaceuticals (6 %)-making it #1 in Canada and the United States.

 
Share this page

You can share this page on :

Contacts

PierreQuirionLife sciences

More details

Jean-MichelGarroLife Sciences

More details

Newsletter

Subscribe to our newsletter for interesting news and information.

Print this page